Xiaosha Zhang
About
Xiaosha Zhang is a scholar working on Hematology, Genetics and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Xiaosha Zhang has authored 22 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 13 papers in Genetics and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiaosha Zhang's work include Hemoglobinopathies and Related Disorders (11 papers), Blood groups and transfusion (7 papers) and Acute Myeloid Leukemia Research (6 papers). Xiaosha Zhang is often cited by papers focused on Hemoglobinopathies and Related Disorders (11 papers), Blood groups and transfusion (7 papers) and Acute Myeloid Leukemia Research (6 papers). Xiaosha Zhang collaborates with scholars based in United States, Germany and Greece. Xiaosha Zhang's co-authors include Kenneth M. Attie, Matthew L. Sherman, Abderrahmane Laadem, Philipp Kiewe, Markus P. Radsak, Aristoteles Giagounidis, Katharina S. Götze, Uwe Platzbecker, Karin Mayer and Thomas Wolff and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Xiaosha Zhang
21 papers receiving 474 citations
Peers
Xiaosha Zhang
Arjan van de Loosdrecht Netherlands
Tiejun Qin China
Ilaria Ambaglio Italy
Alexander J. Silver United States
Rosa Marı́a Arana-Trejo Mexico
Judith Neukirchen Germany
Neng Nie China
Carlos Hader United States
Heather A. Bradeen United States
Marcio Andrade‐Campos Spain
Citations per year, relative to Xiaosha Zhang Xiaosha Zhang (= 1×)
peers
Arjan van de Loosdrecht
Countries citing papers authored by Xiaosha Zhang
Since
Specialization
Citations
This map shows the geographic impact of Xiaosha Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaosha Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaosha Zhang more than expected).
Fields of papers citing papers by Xiaosha Zhang
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Xiaosha Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaosha Zhang. The network helps show where Xiaosha Zhang may publish in the future.
Co-authorship network of co-authors of Xiaosha Zhang
This figure shows the co-authorship network connecting the top 25 collaborators of Xiaosha Zhang. A scholar is included among the top collaborators of Xiaosha Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaosha Zhang. Xiaosha Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gillies, Hunter, Murali M. Chakinala, Benjamin T. Dake, et al.. (2024). IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension. Pulmonary Circulation. 14(1). e12352–e12352.
2.
Piga, Antonio, Filomena Longo, Maria Rita Gamberini, et al.. (2022). Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia. Therapeutic Advances in Hematology. 13. 1554052164–1554052164.
3.
Platzbecker, Uwe, Katharina S. Götze, Philipp Kiewe, et al.. (2022). Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study. Journal of Clinical Oncology. 40(33). 3800–3807.
4.
Platzbecker, Uwe, Philipp Kiewe, Ulrich Germing, et al.. (2020). MDS-191: Long-Term Efficacy and Safety of Luspatercept in Lower-Risk Myelodysplastic Syndromes (MDS): Phase 2 PACE-MDS Study. Clinical Lymphoma Myeloma & Leukemia. 20. S319–S320.
5.
Voss, Martin H., Rupal S. Bhatt, Nicholas J. Vogelzang, et al.. (2019). A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. Cancer. 125(14). 2400–2408.
6.
Piga, Antonio, Silverio Perrotta, Maria Rita Gamberini, et al.. (2019). Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia. Blood. 133(12). 1279–1289.
7.
Taher, Alì, Vip Viprakasit, Maria Domenica Cappellini, et al.. (2018). Development of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO©). American Journal of Hematology. 94(2). 171–176.
8.
Taher, Alì, Maria Domenica Cappellini, Vip Viprakasit, et al.. (2018). Validation of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO©). American Journal of Hematology. 94(2). 177–183.
9.
Platzbecker, Uwe, Ulrich Germing, Katharina S. Götze, et al.. (2017). Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. The Lancet Oncology. 18(10). 1338–1347.
10.
Voss, Martin H., Rupal S. Bhatt, Elizabeth R. Plimack, et al.. (2016). The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. Clinical Cancer Research. 23(14). 3557–3565.
11.
Jimeno, Antonio, Marshall R. Posner, Lori J. Wirth, et al.. (2016). A phase 2 study of dalantercept, an activin receptor‐like kinase‐1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 122(23). 3641–3649.
12.
Chen, Nianhang, Abderrahmane Laadem, Dawn Wilson, et al.. (2016). Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Beta-Thalassemia: Preliminary Results from Phase 2 Studies. Blood. 128(22). 2463–2463.
13.
Piga, Antonio, Immacolata Tartaglione, Rita Gamberini, et al.. (2016). Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia. Blood. 128(22). 851–851.
14.
Platzbecker, Uwe, Ulrich Germing, Katharina S. Götze, et al.. (2016). Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study. Blood. 128(22). 3168–3168.
15.
Giagounidis, Aristoteles, Uwe Platzbecker, Ulrich Germing, et al.. (2015). Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study. Blood. 126(23). 92–92.
16.
Voss, Martin H., Elizabeth R. Plimack, Brian I. Rini, et al.. (2015). DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1.. Journal of Clinical Oncology. 33(7_suppl). 407–407.
17.
Piga, Antonio, Silverio Perrotta, Maria Rita Gamberini, et al.. (2015). Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study. Blood. 126(23). 752–752.
18.
Platzbecker, Uwe, Ulrich Germing, Aristoteles Giagounidis, et al.. (2015). Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study. Blood. 126(23). 2862–2862.
19.
Voss, Martin H., Elizabeth R. Plimack, Brian I. Rini, et al.. (2015). The DART Study: A phase 2 randomized double-blind study of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC).. Journal of Clinical Oncology. 33(15_suppl). TPS4583–TPS4583.
20.
Fang, Fang, et al.. (2013). Methods of designing two‐stage winner trials with survival outcomes. Statistics in Medicine. 33(9). 1539–1563.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Arjan van de Loosdrecht Breakdown of academic impact, for papers by Tiejun Qin Breakdown of academic impact, for papers by Ilaria Ambaglio Breakdown of academic impact, for papers by Alexander J. Silver Breakdown of academic impact, for papers by Rosa Marı́a Arana-Trejo Breakdown of academic impact, for papers by Judith Neukirchen Breakdown of academic impact, for papers by Neng Nie Breakdown of academic impact, for papers by Carlos Hader Breakdown of academic impact, for papers by Heather A. Bradeen Breakdown of academic impact, for papers by Marcio Andrade‐Campos